Home > Press Releases > Organoids & Next-Gen Human In-Vitro Models Market

Organoids & Next-Gen Human In-Vitro Models Market Likely to Surpass USD 1.3 Billion by 2035

Report Code: HC-84163  |  Published in: Nov 2025, By MarketGenics  |  Number of pages: 317
Get PDF
Buy

A significant study discovering the market avenues on, “Organoids & Next-Gen Human In-Vitro Models Market Size, Share & Trends Analysis Report by Product Type (Brain Organoids, Liver Organoids, Kidney Organoids, Intestinal Organoids, Lung Organoids, Cardiac Organoid, Pancreatic Organoids, Tumor Organoids, Other Organoid Types), Technology/Platform, Cell Source, Application, Disease Type, Complexity Level, Scale of Operation, End-users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2026–2035” A holistic view of the market pathways in the organoids & next-gen human in-vitro models market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships

Global Organoids & Next-Gen Human In-Vitro Models Market Forecast 2035:

According to the report, the global organoids & next-gen human in-vitro models market is projected to expand from USD 0.4 billion in 2025 to USD 1.3 billion by 2035, registering a CAGR of 12.6%, the highest during the forecast period. The organoids and next-generation human in-vitro models market is also rapidly developing, owing to the increasing need to have more physiologically relevant and predictive models in biomedical studies. These superior 3D cell-based systems mimic the structure and functionality of human organs and help to model diseases, discover drugs and test toxicity better and minimize the dependence on animal models.

Furthermore, the models are being improved by technological change, such as CRISPR-based genetic engineering, microfluidics, and high-throughput screening. The growth of the market is also being boosted by the fact that there is more investment by pharmaceutical and biotechnology firms and that there is also supportive regulatory frameworks supporting alternatives to animal testing.

Moreover, they are versatile as their main applications include oncology, neurodegenerative diseases, infectious diseases, and personalized medicine. With the growing number of collaborations between academic centers, research institutions, and industry partners, the market is ready to become innovative again, providing a chance to perform preclinical testing in an economical way and human-relevant manner, as well as hasten the translational studies.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Organoids & Next-Gen Human In-Vitro Models Market”

Organoids and next-gen human in-vitro models are growing in the market because of increased investment by pharmaceutical, biotechnology, and research organizations in advanced in-vitro models. R&D, infrastructure, and collaborations funding allow the development and commercialization of organoids and next-gen human models, which can allow faster, cost-effective, and reliable preclinical research and hasten drug discovery and personalized medicine innovations.

The next-gen human in-vitro models market is still facing a major challenge of technical complexity. The creation of reproducible and standardized organoid cultures cannot be achieved without specialized expertise and advanced laboratory infrastructure and control of the culture conditions. The results of these models may not be reproducible because different cell sources and differentiation protocols, or microenvironmental factors could cause variability. Such complexity prevents large-scale adoption, particularly in smaller research laboratories or companies which have limited technical capabilities, decelerates continuing adoption into drug discovery and translational research.

The possibility to integrate the gene-editing technologies, including CRISPR-Cas9 as well as the next-gen imaging models represents further opportunity in the organoids and next-gen human in-vitro models market. The combination allows the genetic diseases to be modeled accurately, allows the discovery of new therapeutic targets, and provides an opportunity to test gene-based interventions in a human-relevant model. It enables the researcher to investigate disease processes on a genetic scale, speed up drug discovery and enhance personalized medicine, which will ultimately enhance the effectiveness of the treatment and patient outcomes.

Expansion of Global Organoids & Next-Gen Human In-Vitro Models Market

“Innovation, and public funding propel the global organoids & next-gen human in-vitro models market expansion”

  • The global organoids and next-gen human in-vitro models market is growing fast, because of the rising demand of human-relevant models in drug development and testing of toxicity. Increasing partnerships between pharmaceuticals, biotech and academic firms are driving innovation, and growing investment in both personalized medicine and high-throughput screening platforms are driving adoption. As an example, In January 2025, Merck KGaA acquired HUB Organoids Holding B. V., an organoid customer in the Netherlands to widen its upcoming-generation biology holdings.
  • Government incentives and funding programs are greatly contributing to the development of the organoids and next-gen human in-vitro models market. As an example, in 2025, the NIH created the Standardized Organoid Modeling (SOM) Center with an investment of US$ 87 million dollars to create standardized, reproducible organoid models through the use of AI and robotics. The center aids truth seekers around the globe, promotes drug discovery and disease kettles, and minimizes the use of animal experiments.

Regional Analysis of Global Organoids & Next-Gen Human In-Vitro Models Market

  • North America dominates the global organoids and human in-vitro models market, because of high investment in biotechnology and pharmaceutical research, well-developed facilities, and a high degree of taking up human-relevant models. Favorable policies favoring alternatives to animal research, efforts in precision medicine, and swift technological breakthroughs such as AI-based imaging and automated organoid cultures increase reproducibility and throughput. The adoption is further supported by industry development such as NIH funding and organoid centers enabling the region as the leading market.
  • The Asia Pacific market has the most rapid expansion in the organoids and next-gen human in-vitro models market associated with the growth of biotechnology and pharmaceutical market, growing healthcare R&D spending, and the growing use of novel organoid and 3D cell models. Furthermore, the adoption of next-generation in-vitro models in drug discovery for disease modeling and toxicology testing, especially in China, Japan, South Korea, and Australia is accelerating the market growth.

Prominent players operating in the global organoids & next-gen human in-vitro models market are Agilent Technologies Inc., CELLINK (BICO Group), CN Bio Innovations, Corning Incorporated, DefiniGEN Ltd., Emulate Inc., Hubrecht Organoid Technology (HUB), InSphero AG, Kirkstall Ltd., Lonza Group AG, Merck KGaA, Mimetas B.V., Molecular Devices LLC, Nortis Inc., Organovo Holdings Inc., PerkinElmer Inc., Sigma-Aldrich, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc., TissUse GmbH, and Other Key Players.

The global organoids & next-gen human in-vitro models market has been segmented as follows:

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Product Type

  • Brain Organoids
  • Liver Organoids
  • Kidney Organoids
  • Intestinal Organoids
  • Lung Organoids
  • Cardiac Organoid
  • Pancreatic Organoids
  • Tumor Organoids
  • Other Organoid Types

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Technology/Platform

  • 3D Cell Culture
  • Microfluidic Systems (Organ-on-a-Chip)
  • Bioprinting Technology
  • Spheroid-based Systems
  • Hydrogel-based Systems
  • Organoid-on-a-Chip
  • Patient-Derived Organoids (PDOs)

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Cell Source

  • Pluripotent Stem Cells
  • Induced Pluripotent Stem Cells (iPSCs)
  • Embryonic Stem Cells (ESCs)
  • Adult Stem Cells
  • Primary Cells
  • Cell Lines

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Application

  • Drug Discovery & Development
    • Target Identification
    • Lead Optimization
    • Efficacy Testing
    • Others
  • Toxicology Testing
    • Hepatotoxicity
    • Cardiotoxicity
    • Nephrotoxicity
    • Neurotoxicity
    • Others
  • Disease Modeling
    • Cancer Research
    • Infectious Diseases
    • Genetic Disorders
    • Neurodegenerative Diseases
    • Others
  • Personalized Medicine
  • Regenerative Medicine
  • Basic Research

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Disease Type

  • Oncology
    • Solid Tumors
    • Hematological Malignancies
  • Neurological Disorders
    • Alzheimer's Disease
    • Parkinson's Disease
    • Epilepsy
    • Others
  • Metabolic Disorders
  • Cardiovascular Diseases
  • Gastrointestinal Disorders
  • Respiratory Diseases
  • Infectious Diseases

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Complexity Level

  • Simple Organoids (Single Cell Type)
  • Complex Organoids (Multiple Cell Types)
  • Assembloids (Fused Organoids)
  • Vascularized Organoids

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Scale of Operation

  • Research Scale
  • Preclinical Scale
  • Clinical Scale
  • Commercial Production Scale

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By End-users

  • Pharmaceutical & Biotechnology Companies
    • Drug Discovery
    • Preclinical Testing
    • Toxicity Screening
    • Target Validation
    • Drug Repurposing
    • Others
  • Academic & Research Institutions
    • Basic Research
    • Disease Mechanism Studies
    • Genetic Research
    • Developmental Biology Studies
    • Publications & Studies
    • Others
  • Contract Research Organizations (CROs)
    • Preclinical Services
    • Toxicology Testing Services
    • Efficacy Studies
    • Custom Research Projects
    • Others
  • Hospitals & Diagnostic Centers
    • Personalized Treatment Planning
    • Disease Diagnosis
    • Patient-Specific Drug Testing
    • Precision Medicine
    • Others
  • Cosmetic & Chemical Industries
    • Safety Testing
    • Product Development
    • Alternative to Animal Testing
    • Regulatory Compliance Testing
    • Others
  • Agricultural Biotechnology
    • Pesticide Testing
    • Crop Protection Research
    • Toxicity Assessment
    • Others
  • Other End-users

Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America
 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Organoids & Next-Gen Human In-Vitro Models Market Outlook
      • 2.1.1. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
        • 3.5.1.1. Manufacturer
        • 3.5.1.2. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising demand for more predictive preclinical models
        • 4.1.1.2. Technological advancements in organoid and in-vitro platforms
        • 4.1.1.3. Increased pharmaceutical outsourcing for drug discovery
      • 4.1.2. Restraints
        • 4.1.2.1. High cost of organoid and next-gen model development.
        • 4.1.2.2. Limited regulatory acceptance for clinical submissions
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
      • 4.4.1. Raw Material Suppliers
      • 4.4.2. Organoids & Next-Gen Human In-Vitro Models Manufacturers
      • 4.4.3. Dealers/ Distributors
      • 4.4.4. End-Users/ Customers
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Organoids & Next-Gen Human In-Vitro Models Market Demand
      • 4.7.1. Historical Market Size –Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size –Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Product Type
    • 6.1. Key Segment Analysis
    • 6.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By Product Type, 2021-2035
      • 6.2.1. Brain Organoids
      • 6.2.2. Liver Organoids
      • 6.2.3. Kidney Organoids
      • 6.2.4. Intestinal Organoids
      • 6.2.5. Lung Organoids
      • 6.2.6. Cardiac Organoid
      • 6.2.7. Pancreatic Organoids
      • 6.2.8. Tumor Organoids
      • 6.2.9. Other Organoid Types
  • 7. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Technology/Platform
    • 7.1. Key Segment Analysis
    • 7.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By Technology/Platform, 2021-2035
      • 7.2.1. 3D Cell Culture
      • 7.2.2. Microfluidic Systems (Organ-on-a-Chip)
      • 7.2.3. Bioprinting Technology
      • 7.2.4. Spheroid-based Systems
      • 7.2.5. Hydrogel-based Systems
      • 7.2.6. Organoid-on-a-Chip
      • 7.2.7. Patient-Derived Organoids (PDOs)
  • 8. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Cell Source
    • 8.1. Key Segment Analysis
    • 8.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By Cell Source, 2021-2035
      • 8.2.1. Pluripotent Stem Cells
      • 8.2.2. Induced Pluripotent Stem Cells (iPSCs)
      • 8.2.3. Embryonic Stem Cells (ESCs)
      • 8.2.4. Adult Stem Cells
      • 8.2.5. Primary Cells
      • 8.2.6. Cell Lines
  • 9. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Application
    • 9.1. Key Segment Analysis
    • 9.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By Application, 2021-2035
      • 9.2.1. Drug Discovery & Development
        • 9.2.1.1. Target Identification
        • 9.2.1.2. Lead Optimization
        • 9.2.1.3. Efficacy Testing
        • 9.2.1.4. Others
      • 9.2.2. Toxicology Testing
        • 9.2.2.1. Hepatotoxicity
        • 9.2.2.2. Cardiotoxicity
        • 9.2.2.3. Nephrotoxicity
        • 9.2.2.4. Neurotoxicity
        • 9.2.2.5. Others
      • 9.2.3. Disease Modeling
        • 9.2.3.1. Cancer Research
        • 9.2.3.2. Infectious Diseases
        • 9.2.3.3. Genetic Disorders
        • 9.2.3.4. Neurodegenerative Diseases
        • 9.2.3.5. Others
      • 9.2.4. Personalized Medicine
      • 9.2.5. Regenerative Medicine
      • 9.2.6. Basic Research
  • 10. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Disease Type
    • 10.1. Key Segment Analysis
    • 10.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By Disease Type, 2021-2035
      • 10.2.1. Oncology
        • 10.2.1.1. Solid Tumors
        • 10.2.1.2. Hematological Malignancies
      • 10.2.2. Neurological Disorders
        • 10.2.2.1. Alzheimer's Disease
        • 10.2.2.2. Parkinson's Disease
        • 10.2.2.3. Epilepsy
        • 10.2.2.4. Others
      • 10.2.3. Metabolic Disorders
      • 10.2.4. Cardiovascular Diseases
      • 10.2.5. Gastrointestinal Disorders
      • 10.2.6. Respiratory Diseases
      • 10.2.7. Infectious Diseases
  • 11. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Complexity Level
    • 11.1. Key Segment Analysis
    • 11.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By Complexity Level, 2021-2035
      • 11.2.1. Simple Organoids (Single Cell Type)
      • 11.2.2. Complex Organoids (Multiple Cell Types)
      • 11.2.3. Assembloids (Fused Organoids)
      • 11.2.4. Vascularized Organoids
  • 12. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By Scale of Operation
    • 12.1. Key Segment Analysis
    • 12.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By Scale of Operation, 2021-2035
      • 12.2.1. Research Scale
      • 12.2.2. Preclinical Scale
      • 12.2.3. Clinical Scale
      • 12.2.4. Commercial Production Scale
  • 13. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis, By End-users
    • 13.1. Key Segment Analysis
    • 13.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, By End-users, 2021-2035
      • 13.2.1. Pharmaceutical & Biotechnology Companies
        • 13.2.1.1. Drug Discovery
        • 13.2.1.2. Preclinical Testing
        • 13.2.1.3. Toxicity Screening
        • 13.2.1.4. Target Validation
        • 13.2.1.5. Drug Repurposing
        • 13.2.1.6. Others
      • 13.2.2. Academic & Research Institutions
        • 13.2.2.1. Basic Research
        • 13.2.2.2. Disease Mechanism Studies
        • 13.2.2.3. Genetic Research
        • 13.2.2.4. Developmental Biology Studies
        • 13.2.2.5. Publications & Studies
        • 13.2.2.6. Others
      • 13.2.3. Contract Research Organizations (CROs)
        • 13.2.3.1. Preclinical Services
        • 13.2.3.2. Toxicology Testing Services
        • 13.2.3.3. Efficacy Studies
        • 13.2.3.4. Custom Research Projects
        • 13.2.3.5. Others
      • 13.2.4. Hospitals & Diagnostic Centers
        • 13.2.4.1. Personalized Treatment Planning
        • 13.2.4.2. Disease Diagnosis
        • 13.2.4.3. Patient-Specific Drug Testing
        • 13.2.4.4. Precision Medicine
        • 13.2.4.5. Others
      • 13.2.5. Cosmetic & Chemical Industries
        • 13.2.5.1. Safety Testing
        • 13.2.5.2. Product Development
        • 13.2.5.3. Alternative to Animal Testing
        • 13.2.5.4. Regulatory Compliance Testing
        • 13.2.5.5. Others
      • 13.2.6. Agricultural Biotechnology
        • 13.2.6.1. Pesticide Testing
        • 13.2.6.2. Crop Protection Research
        • 13.2.6.3. Toxicity Assessment
        • 13.2.6.4. Others
      • 13.2.7. Other End-users
  • 14. Global Organoids & Next-Gen Human In-Vitro Models Market Analysis and Forecasts, by Region
    • 14.1. Key Findings
    • 14.2. Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 14.2.1. North America
      • 14.2.2. Europe
      • 14.2.3. Asia Pacific
      • 14.2.4. Middle East
      • 14.2.5. Africa
      • 14.2.6. South America
  • 15. North America Organoids & Next-Gen Human In-Vitro Models Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. North America Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Product Type
      • 15.3.2. Technology/Platform
      • 15.3.3. Cell Source
      • 15.3.4. Application
      • 15.3.5. Disease Type
      • 15.3.6. Complexity Level
      • 15.3.7. Scale of Operation
      • 15.3.8. End-users
      • 15.3.9. Country
        • 15.3.9.1. USA
        • 15.3.9.2. Canada
        • 15.3.9.3. Mexico
    • 15.4. USA Organoids & Next-Gen Human In-Vitro Models Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Product Type
      • 15.4.3. Technology/Platform
      • 15.4.4. Cell Source
      • 15.4.5. Application
      • 15.4.6. Disease Type
      • 15.4.7. Complexity Level
      • 15.4.8. Scale of Operation
      • 15.4.9. End-users
    • 15.5. Canada Organoids & Next-Gen Human In-Vitro Models Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Product Type
      • 15.5.3. Technology/Platform
      • 15.5.4. Cell Source
      • 15.5.5. Application
      • 15.5.6. Disease Type
      • 15.5.7. Complexity Level
      • 15.5.8. Scale of Operation
      • 15.5.9. End-users
    • 15.6. Mexico Organoids & Next-Gen Human In-Vitro Models Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Product Type
      • 15.6.3. Technology/Platform
      • 15.6.4. Cell Source
      • 15.6.5. Application
      • 15.6.6. Disease Type
      • 15.6.7. Complexity Level
      • 15.6.8. Scale of Operation
      • 15.6.9. End-users
  • 16. Europe Organoids & Next-Gen Human In-Vitro Models Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Europe Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Product Type
      • 16.3.2. Technology/Platform
      • 16.3.3. Cell Source
      • 16.3.4. Application
      • 16.3.5. Disease Type
      • 16.3.6. Complexity Level
      • 16.3.7. Scale of Operation
      • 16.3.8. End-users
      • 16.3.9. Country
        • 16.3.9.1. Germany
        • 16.3.9.2. United Kingdom
        • 16.3.9.3. France
        • 16.3.9.4. Italy
        • 16.3.9.5. Spain
        • 16.3.9.6. Netherlands
        • 16.3.9.7. Nordic Countries
        • 16.3.9.8. Poland
        • 16.3.9.9. Russia & CIS
        • 16.3.9.10. Rest of Europe
    • 16.4. Germany Organoids & Next-Gen Human In-Vitro Models Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Product Type
      • 16.4.3. Technology/Platform
      • 16.4.4. Cell Source
      • 16.4.5. Application
      • 16.4.6. Disease Type
      • 16.4.7. Complexity Level
      • 16.4.8. Scale of Operation
      • 16.4.9. End-users
    • 16.5. United Kingdom Organoids & Next-Gen Human In-Vitro Models Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Product Type
      • 16.5.3. Technology/Platform
      • 16.5.4. Cell Source
      • 16.5.5. Application
      • 16.5.6. Disease Type
      • 16.5.7. Complexity Level
      • 16.5.8. Scale of Operation
      • 16.5.9. End-users
    • 16.6. France Organoids & Next-Gen Human In-Vitro Models Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Product Type
      • 16.6.3. Technology/Platform
      • 16.6.4. Cell Source
      • 16.6.5. Application
      • 16.6.6. Disease Type
      • 16.6.7. Complexity Level
      • 16.6.8. Scale of Operation
      • 16.6.9. End-users
    • 16.7. Italy Organoids & Next-Gen Human In-Vitro Models Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Product Type
      • 16.7.3. Technology/Platform
      • 16.7.4. Cell Source
      • 16.7.5. Application
      • 16.7.6. Disease Type
      • 16.7.7. Complexity Level
      • 16.7.8. Scale of Operation
      • 16.7.9. End-users
    • 16.8. Spain Organoids & Next-Gen Human In-Vitro Models Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Product Type
      • 16.8.3. Technology/Platform
      • 16.8.4. Cell Source
      • 16.8.5. Application
      • 16.8.6. Disease Type
      • 16.8.7. Complexity Level
      • 16.8.8. Scale of Operation
      • 16.8.9. End-users
    • 16.9. Netherlands Organoids & Next-Gen Human In-Vitro Models Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Product Type
      • 16.9.3. Technology/Platform
      • 16.9.4. Cell Source
      • 16.9.5. Application
      • 16.9.6. Disease Type
      • 16.9.7. Complexity Level
      • 16.9.8. Scale of Operation
      • 16.9.9. End-users
    • 16.10. Nordic Countries Organoids & Next-Gen Human In-Vitro Models Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Product Type
      • 16.10.3. Technology/Platform
      • 16.10.4. Cell Source
      • 16.10.5. Application
      • 16.10.6. Disease Type
      • 16.10.7. Complexity Level
      • 16.10.8. Scale of Operation
      • 16.10.9. End-users
    • 16.11. Poland Organoids & Next-Gen Human In-Vitro Models Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Product Type
      • 16.11.3. Technology/Platform
      • 16.11.4. Cell Source
      • 16.11.5. Application
      • 16.11.6. Disease Type
      • 16.11.7. Complexity Level
      • 16.11.8. Scale of Operation
      • 16.11.9. End-users
    • 16.12. Russia & CIS Organoids & Next-Gen Human In-Vitro Models Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Product Type
      • 16.12.3. Technology/Platform
      • 16.12.4. Cell Source
      • 16.12.5. Application
      • 16.12.6. Disease Type
      • 16.12.7. Complexity Level
      • 16.12.8. Scale of Operation
      • 16.12.9. End-users
    • 16.13. Rest of Europe Organoids & Next-Gen Human In-Vitro Models Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Product Type
      • 16.13.3. Technology/Platform
      • 16.13.4. Cell Source
      • 16.13.5. Application
      • 16.13.6. Disease Type
      • 16.13.7. Complexity Level
      • 16.13.8. Scale of Operation
      • 16.13.9. End-users
  • 17. Asia Pacific Organoids & Next-Gen Human In-Vitro Models Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Asia Pacific Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Product Type
      • 17.3.2. Technology/Platform
      • 17.3.3. Cell Source
      • 17.3.4. Application
      • 17.3.5. Disease Type
      • 17.3.6. Complexity Level
      • 17.3.7. Scale of Operation
      • 17.3.8. End-users
      • 17.3.9. Country
        • 17.3.9.1. China
        • 17.3.9.2. India
        • 17.3.9.3. Japan
        • 17.3.9.4. South Korea
        • 17.3.9.5. Australia and New Zealand
        • 17.3.9.6. Indonesia
        • 17.3.9.7. Malaysia
        • 17.3.9.8. Thailand
        • 17.3.9.9. Vietnam
        • 17.3.9.10. Rest of Asia Pacific
    • 17.4. China Organoids & Next-Gen Human In-Vitro Models Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Product Type
      • 17.4.3. Technology/Platform
      • 17.4.4. Cell Source
      • 17.4.5. Application
      • 17.4.6. Disease Type
      • 17.4.7. Complexity Level
      • 17.4.8. Scale of Operation
      • 17.4.9. End-users
    • 17.5. India Organoids & Next-Gen Human In-Vitro Models Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Product Type
      • 17.5.3. Technology/Platform
      • 17.5.4. Cell Source
      • 17.5.5. Application
      • 17.5.6. Disease Type
      • 17.5.7. Complexity Level
      • 17.5.8. Scale of Operation
      • 17.5.9. End-users
    • 17.6. Japan Organoids & Next-Gen Human In-Vitro Models Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Product Type
      • 17.6.3. Technology/Platform
      • 17.6.4. Cell Source
      • 17.6.5. Application
      • 17.6.6. Disease Type
      • 17.6.7. Complexity Level
      • 17.6.8. Scale of Operation
      • 17.6.9. End-users
    • 17.7. South Korea Organoids & Next-Gen Human In-Vitro Models Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Product Type
      • 17.7.3. Technology/Platform
      • 17.7.4. Cell Source
      • 17.7.5. Application
      • 17.7.6. Disease Type
      • 17.7.7. Complexity Level
      • 17.7.8. Scale of Operation
      • 17.7.9. End-users
    • 17.8. Australia and New Zealand Organoids & Next-Gen Human In-Vitro Models Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Product Type
      • 17.8.3. Technology/Platform
      • 17.8.4. Cell Source
      • 17.8.5. Application
      • 17.8.6. Disease Type
      • 17.8.7. Complexity Level
      • 17.8.8. Scale of Operation
      • 17.8.9. End-users
    • 17.9. Indonesia Organoids & Next-Gen Human In-Vitro Models Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Product Type
      • 17.9.3. Technology/Platform
      • 17.9.4. Cell Source
      • 17.9.5. Application
      • 17.9.6. Disease Type
      • 17.9.7. Complexity Level
      • 17.9.8. Scale of Operation
      • 17.9.9. End-users
    • 17.10. Malaysia Organoids & Next-Gen Human In-Vitro Models Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Product Type
      • 17.10.3. Technology/Platform
      • 17.10.4. Cell Source
      • 17.10.5. Application
      • 17.10.6. Disease Type
      • 17.10.7. Complexity Level
      • 17.10.8. Scale of Operation
      • 17.10.9. End-users
    • 17.11. Thailand Organoids & Next-Gen Human In-Vitro Models Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Product Type
      • 17.11.3. Technology/Platform
      • 17.11.4. Cell Source
      • 17.11.5. Application
      • 17.11.6. Disease Type
      • 17.11.7. Complexity Level
      • 17.11.8. Scale of Operation
      • 17.11.9. End-users
    • 17.12. Vietnam Organoids & Next-Gen Human In-Vitro Models Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Product Type
      • 17.12.3. Technology/Platform
      • 17.12.4. Cell Source
      • 17.12.5. Application
      • 17.12.6. Disease Type
      • 17.12.7. Complexity Level
      • 17.12.8. Scale of Operation
      • 17.12.9. End-users
    • 17.13. Rest of Asia Pacific Organoids & Next-Gen Human In-Vitro Models Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Product Type
      • 17.13.3. Technology/Platform
      • 17.13.4. Cell Source
      • 17.13.5. Application
      • 17.13.6. Disease Type
      • 17.13.7. Complexity Level
      • 17.13.8. Scale of Operation
      • 17.13.9. End-users
  • 18. Middle East Organoids & Next-Gen Human In-Vitro Models Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Middle East Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Product Type
      • 18.3.2. Technology/Platform
      • 18.3.3. Cell Source
      • 18.3.4. Application
      • 18.3.5. Disease Type
      • 18.3.6. Complexity Level
      • 18.3.7. Scale of Operation
      • 18.3.8. End-users
      • 18.3.9. Country
        • 18.3.9.1. Turkey
        • 18.3.9.2. UAE
        • 18.3.9.3. Saudi Arabia
        • 18.3.9.4. Israel
        • 18.3.9.5. Rest of Middle East
    • 18.4. Turkey Organoids & Next-Gen Human In-Vitro Models Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Product Type
      • 18.4.3. Technology/Platform
      • 18.4.4. Cell Source
      • 18.4.5. Application
      • 18.4.6. Disease Type
      • 18.4.7. Complexity Level
      • 18.4.8. Scale of Operation
      • 18.4.9. End-users
    • 18.5. UAE Organoids & Next-Gen Human In-Vitro Models Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Product Type
      • 18.5.3. Technology/Platform
      • 18.5.4. Cell Source
      • 18.5.5. Application
      • 18.5.6. Disease Type
      • 18.5.7. Complexity Level
      • 18.5.8. Scale of Operation
      • 18.5.9. End-users
    • 18.6. Saudi Arabia Organoids & Next-Gen Human In-Vitro Models Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Product Type
      • 18.6.3. Technology/Platform
      • 18.6.4. Cell Source
      • 18.6.5. Application
      • 18.6.6. Disease Type
      • 18.6.7. Complexity Level
      • 18.6.8. Scale of Operation
      • 18.6.9. End-users
    • 18.7. Israel Organoids & Next-Gen Human In-Vitro Models Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Product Type
      • 18.7.3. Technology/Platform
      • 18.7.4. Cell Source
      • 18.7.5. Application
      • 18.7.6. Disease Type
      • 18.7.7. Complexity Level
      • 18.7.8. Scale of Operation
      • 18.7.9. End-users l
    • 18.8. Rest of Middle East Organoids & Next-Gen Human In-Vitro Models Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Product Type
      • 18.8.3. Technology/Platform
      • 18.8.4. Cell Source
      • 18.8.5. Application
      • 18.8.6. Disease Type
      • 18.8.7. Complexity Level
      • 18.8.8. Scale of Operation
      • 18.8.9. End-users
  • 19. Africa Organoids & Next-Gen Human In-Vitro Models Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Africa Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Product Type
      • 19.3.2. Technology/Platform
      • 19.3.3. Cell Source
      • 19.3.4. Application
      • 19.3.5. Disease Type
      • 19.3.6. Complexity Level
      • 19.3.7. Scale of Operation
      • 19.3.8. End-users
      • 19.3.9. Country
        • 19.3.9.1. South Africa
        • 19.3.9.2. Egypt
        • 19.3.9.3. Nigeria
        • 19.3.9.4. Algeria
        • 19.3.9.5. Rest of Africa
    • 19.4. South Africa Organoids & Next-Gen Human In-Vitro Models Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Product Type
      • 19.4.3. Technology/Platform
      • 19.4.4. Cell Source
      • 19.4.5. Application
      • 19.4.6. Disease Type
      • 19.4.7. Complexity Level
      • 19.4.8. Scale of Operation
      • 19.4.9. End-users
    • 19.5. Egypt Organoids & Next-Gen Human In-Vitro Models Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Product Type
      • 19.5.3. Technology/Platform
      • 19.5.4. Cell Source
      • 19.5.5. Application
      • 19.5.6. Disease Type
      • 19.5.7. Complexity Level
      • 19.5.8. Scale of Operation
      • 19.5.9. End-users
    • 19.6. Nigeria Organoids & Next-Gen Human In-Vitro Models Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Product Type
      • 19.6.3. Technology/Platform
      • 19.6.4. Cell Source
      • 19.6.5. Application
      • 19.6.6. Disease Type
      • 19.6.7. Complexity Level
      • 19.6.8. Scale of Operation
      • 19.6.9. End-users
    • 19.7. Algeria Organoids & Next-Gen Human In-Vitro Models Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Product Type
      • 19.7.3. Technology/Platform
      • 19.7.4. Cell Source
      • 19.7.5. Application
      • 19.7.6. Disease Type
      • 19.7.7. Complexity Level
      • 19.7.8. Scale of Operation
      • 19.7.9. End-users
    • 19.8. Rest of Africa Organoids & Next-Gen Human In-Vitro Models Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Product Type
      • 19.8.3. Technology/Platform
      • 19.8.4. Cell Source
      • 19.8.5. Application
      • 19.8.6. Disease Type
      • 19.8.7. Complexity Level
      • 19.8.8. Scale of Operation
      • 19.8.9. End-users
  • 20. South America Organoids & Next-Gen Human In-Vitro Models Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. South America Organoids & Next-Gen Human In-Vitro Models Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Product Type
      • 20.3.2. Technology/Platform
      • 20.3.3. Cell Source
      • 20.3.4. Application
      • 20.3.5. Disease Type
      • 20.3.6. Complexity Level
      • 20.3.7. Scale of Operation
      • 20.3.8. End-users
      • 20.3.9. Country
        • 20.3.9.1. Brazil
        • 20.3.9.2. Argentina
        • 20.3.9.3. Rest of South America
    • 20.4. Brazil Organoids & Next-Gen Human In-Vitro Models Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Product Type
      • 20.4.3. Technology/Platform
      • 20.4.4. Cell Source
      • 20.4.5. Application
      • 20.4.6. Disease Type
      • 20.4.7. Complexity Level
      • 20.4.8. Scale of Operation
      • 20.4.9. End-users
    • 20.5. Argentina Organoids & Next-Gen Human In-Vitro Models Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Product Type
      • 20.5.3. Technology/Platform
      • 20.5.4. Cell Source
      • 20.5.5. Application
      • 20.5.6. Disease Type
      • 20.5.7. Complexity Level
      • 20.5.8. Scale of Operation
      • 20.5.9. End-users
    • 20.6. Rest of South America Organoids & Next-Gen Human In-Vitro Models Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Product Type
      • 20.6.3. Technology/Platform
      • 20.6.4. Cell Source
      • 20.6.5. Application
      • 20.6.6. Disease Type
      • 20.6.7. Complexity Level
      • 20.6.8. Scale of Operation
      • 20.6.9. End-users
  • 21. Key Players/ Company Profile
    • 21.1. Agilent Technologies Inc.
      • 21.1.1. Company Details/ Overview
      • 21.1.2. Company Financials
      • 21.1.3. Key Customers and Competitors
      • 21.1.4. Business/ Industry Portfolio
      • 21.1.5. Product Portfolio/ Specification Details
      • 21.1.6. Pricing Data
      • 21.1.7. Strategic Overview
      • 21.1.8. Recent Developments
    • 21.2. CELLINK (BICO Group)
    • 21.3. CN Bio Innovations
    • 21.4. Corning Incorporated
    • 21.5. DefiniGEN Ltd.
    • 21.6. Emulate Inc.
    • 21.7. Hubrecht Organoid Technology (HUB)
    • 21.8. InSphero AG
    • 21.9. Kirkstall Ltd.
    • 21.10. Lonza Group AG
    • 21.11. Merck KGaA
    • 21.12. Mimetas B.V.
    • 21.13. Molecular Devices LLC
    • 21.14. Nortis Inc.
    • 21.15. Organovo Holdings Inc.
    • 21.16. PerkinElmer Inc.
    • 21.17. Sigma-Aldrich
    • 21.18. STEMCELL Technologies Inc.
    • 21.19. Thermo Fisher Scientific Inc.
    • 21.20. TissUse GmbH
    • 21.21. Other Key Players

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation